Determined pharmaceutical sales professional with a strong critical care background and a proven history of driving business growth in various product portfolios at Bristol Myers Squibb, Johnson & Johnson, and Abbott Laboratories. Skilled in navigating competitive marketplaces, passionate about contributing to a forward-thinking organization, improving patient outcomes, and advancing as a leader within the HOCM space.
Currently representing the first and only FDA-approved cardiac myosin inhibitor Camzyos for Obstructive Hypertrophic Cardiomyopathy and Eliquis for Non-Valvular Atrial Fibrillation and Venous Thromboembolism. Targets include Cardiologists, Hospital, Cardiovascular Centers, Sonographers, and Primary Care.
Represented Factor Xa Anticoagulant Xarelto. Achieved 156% avg. PTG forshare growth in one year, to outpace district, region, and nation. Ranked #1/300 in Q2 2024. Targets included MD/PA/NP/PharmD in Cardiology, Hematology/Oncology, Vascular Surgery, and Internal Medicine.
Exceeded annual sales targets by 28%, promoting usage of amino acid formula Elecare in children's hospitals and gastroenterology clinics. Ranked top 10% in 2023.
Functioned fully and independently within the Critical Care Registered Nurse scope of practice.
Territory Management, Specialty Pharmacies, Sales Presentations, Access Navigation, Risk Evaluation Mitigation Strategy, Virtual Platforms, Business Acumen, Goal Setting, Competitive Analysis, Clinical Selling, Competitive Selling, Physician Relations, Collaboration with matrix partners, Leadership Roles, Desire to win